Returning the Right Bacteria to Its Rightful Place

At Pendulum, we develop novel interventions for chronic diseases by identifying bacteria along with specific microbiome elements that work together to positively affect human health and disease management.

Why Your Microbiome Matters

The human microbiome is an ecosystem of trillions of bacteria that work symbiotically with the body to perform essential tasks. These living microorganisms, also known as beneficial bacteria, can offer diverse health benefits.

In the past 10 years, research of the microbiome has shown deficiencies that have been linked to a range of diseases including diabetes, autism, depression, cardiovascular, cancer and Parkinson’s Disease.

We now know that deficits in certain bacterial functions have been linked with chronic diseases, and the re-introduction of those bacteria can restore function, alleviate symptoms and perhaps reverse the diseases.

Pioneers of Discovery

Pendulum has pioneered the ability to identify novel bacteria and validate their potential for affecting human health. We use our high resolution data and analytical tools to identify specific microbiome markers and novel interventions.

Our Data-driven, Integrated Approach

We apply a unique approach to the development of medical interventions with a team of technical specialists across Lab, Compute, and Clinical teams.

We use cutting edge technology to identify, test and measure novel strains and microbiome solutions to create and deliver products with high efficacy. Our integrated, iterative process enables rapid testing and development of efficacious products.

The Pendulum Pipeline

Pendulum is developing a range of microbiome solutions to help improve patient health and well-being. The company’s current pipeline includes pre-clinical and clinical trials focused on novel microbiome interventions in key areas, including diabetes and IBS.

Type 2 Diabetes

Through years of research and an integrated, iterative process for discovery and testing, Pendulum has pinpointed specific beneficial bacteria and their functions that are missing in people with type 2 diabetes.

In a key clinical trial, our Pendulum Glucose Control product was shown to lower A1C levels and reduce post-meal blood sugar spikes in people with type 2 diabetes.*

"Pendulum's approach is most likely to lead to significant clinical advances.”

—Dr. Robert Ratner
Former Chief Medical Officer of the American Diabetes Association

Learn More

Irritable Bowel Syndrome

Pendulum has pinpointed specific microbiome functions that may help in the management of IBS symptoms.

Dr. Jay Pasricha, the Head of Neurogastroenterology at Johns Hopkins University, performed preclinical studies on our proprietary microbial approach, which were presented at the Annual Digestive Disease Week Conference. Results show that our proprietary synbiotic reduced both pain and anxiety.

“This synbiotic has the potential for broad therapeutic effects on the gut brain axis in IBS.”

—Dr. Jay Pasricha


  1. 1. A metagenome-wide association study of gut microbiota in type 2 diabetes

    Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. Nature (2012) 490:55–60. doi: 10.1038/nature11450

  2. 2. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome

    Vrieze A., Van Nood E., Holleman F., Salojärvi J., Kootte R.S., Bartelsman J.F., Dallinga-Thie G.M., Ackermans M.T., Serlie M.J., Oozeer R., et al. Gastroenterology.

  3. 3. Gut metagenome in European women with normal, impaired and diabetic glucose control.

    Karlsson F.H., Tremaroli V., Nookaew I., Bergström G., Behre C.J., Fagerberg B., Nielsen J., Bäckhed F. Nature. 2013

  4. 4. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota.

    Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, et al. Nature (2015) 528:262–6.

  5. 5. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptorFFAR2.

    Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, et al. Diabetes (2013) 61:364–71.

  1. 6. Sodium butyrate supplementation ameliorates diabetic inflammation in db/db mice.

    Xu YH, Gao CL, Guo HL, Zhang WQ, Huang W, Tang SS, et al. J Endocrinol. (2018) 238:231–44.

  2. 7. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes.

    Zhao, L.; Zhang, F.; Ding, X.; Wu, G.; Lam, Y.Y.; Wang, X.; Fu, H.; Xue, X.; Lu, C.; Ma, J.; et al. Science 2018, 359, 1151–1156.

  3. 8. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases

    Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011;17(12):1519-28.

  4. 9. Improvement of Insulin Sensitivity after Lean Donor Faeces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition.

    Kootte R.S., Levin E., Salojärvi J., Smits L.P., Hartstra A.V., Udayappan S.D., Hermes G., Bouter K.E., Koopen A.M., Holst J.J., et al. Cell Metab. 2017:611–619.

Microbiome Science

Learn more about our microbiome discoveries, science and research.